At Bancorp Lowers stake in Hologic (HOLX)

Hologic (HOLX) : At Bancorp reduced its stake in Hologic by 12.78% during the most recent quarter end. The investment management company now holds a total of 120,393 shares of Hologic which is valued at $4,613,460 after selling 17,636 shares in Hologic , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Hologic makes up approximately 0.65% of At Bancorp’s portfolio.

Other Hedge Funds, Including , Raymond James Trust N.a. reduced its stake in HOLX by selling 19 shares or 0.09% in the most recent quarter. The Hedge Fund company now holds 21,970 shares of HOLX which is valued at $879,899. Hologic makes up approx 0.08% of Raymond James Trust N.a.’s portfolio.Advisory Services Network reduced its stake in HOLX by selling 866 shares or 35.07% in the most recent quarter. The Hedge Fund company now holds 1,603 shares of HOLX which is valued at $63,703. Hologic makes up approx 0.01% of Advisory Services Network’s portfolio.Curbstone Financial Management Corp reduced its stake in HOLX by selling 350 shares or 2.63% in the most recent quarter. The Hedge Fund company now holds 12,956 shares of HOLX which is valued at $512,151. Hologic makes up approx 0.17% of Curbstone Financial Management Corp’s portfolio.

Hologic closed down -1.36 points or -3.40% at $38.69 with 20,91,446 shares getting traded on Tuesday. Post opening the session at $39.79, the shares hit an intraday low of $38.58 and an intraday high of $40 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Hologic reported $0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.48. The company had revenue of $717.40 million for the quarter, compared to analysts expectations of $703.38 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.

Many Wall Street Analysts have commented on Hologic. Company shares were Reiterated by RBC Capital Mkts on Aug 1, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 39 from a previous price target of $37 .

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.